Tail-Phase Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in HIV-Uninfected Adults: HPTN 077
Year: 2019
Type: preprint
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.3445549
Authors: Raphael Landovitz, Sue Li, Joseph J. Eron Jr., Beatriz Grinsztejn, Halima Dawood, Albert Y. Liu, Manya Magnus, Mina C. Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Paul Richardson, Mark A. Marzinke, Susan Eshleman, Ryan Kofron, Adeola Adeyeye, David Burns, Alex R. Rinehart, David Margolis, Myron S. Cohen, Marybeth McCauley, Craig W. Hendrix
Institutions: University of California, Los Angeles, Fred Hutch Cancer Center, University of North Carolina at Chapel Hill, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, San Francisco Department of Public Health, George Washington University, Chris Hani Baragwanath Hospital, Perinatal HIV Research Unit, Johns Hopkins University, Government of the United States of America, National Institute of Allergy and Infectious Diseases, National Institutes of Health, ViiV Healthcare (United Kingdom), Family Health International 360
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3157300339